Safety of bronchodilator reversibility test in elderly subjects: a prospective study

Anna Dor-Wojnarowska¹, Anna Parużyńska², Aleksandra Kulczak², Marta Majewska-Pulsakowska¹, Małgorzata Szymala-Pędzik², Zbigniew Machaj², Małgorzata Sobieszczańska¹, Małgorzata Poręba³

¹Department and Clinic of Internal Medicine and Allergology, Wroclaw Medical University, Wroclaw, Poland
²Department and Clinic of Geriatrics, Wroclaw Medical University, Wroclaw, Poland
³Department of Pathophysiology, Wroclaw Medical University, Wroclaw, Poland

Adv Dermatol Allergol
DOI: https://doi.org/10.5114/ada.2020.92515

Abstract

Introduction: The reversibility test measures an increase in ventilation parameters after the administration of 400 µg of a short-acting β-agonist (SABA). It is worth noting that a typical dosage, applied as a rescue medicine for bronchospastic dyspnoea, is significantly less, i.e., 100–200 µg.

Aim: To assess the effects of inhaled 400 µg fenoterol (in the bronchodilator reversibility test) on the heart rate and the development of tachyarrhythmias in subjects aged 65 and above.

Material and methods: A total of 53 subjects (45 women) aged 77; 68–82 (median; interquartile range) in stable clinical condition were included in the study. Data including medical history, physical examinations, blood biochemistry, chest X-ray, 12-lead electrocardiogram, 24-hour Holter ECG monitoring, bronchodilator test, and echocardiography were obtained. During the Holter ECG monitoring, the bronchodilator test using 400 µg fenoterol (Berotec pMDI) was performed.

Results: A slight but statistically significant (p = 0.02) increase in heart rate from 71 to 75 per min (median) was noted after the administration of fenoterol. No statistically significant differences were found in the number of extrasystolic beats of either supraventricular (p = 0.42) or ventricular origin (p = 0.50). In addition, the subjects did not show any potentially dangerous arrhythmias or significant signs of coronary artery disease. However, there was a significant increase in the number of supraventricular beats in the subjects who were not taking β-blockers.

Conclusions: The use of 400 µg fenoterol in a bronchodilator reversibility test in elderly subjects does not entail any significant cardiovascular risk.

Key words: 24-hour Holter ECG monitoring, bronchodilator test, elderly subjects.
lead to pulmonary shunt and decrease in diastolic pressure [5].

Previous studies have reported the frequent incidence of unstable angina pectoris and myocardial infarction (MI) in subjects taking both short- and long-acting β-adrenergic medicines [6–9]. Lee et al. [6] found that the estimated risk of myocardial infarction among new users of β-adrenergics was significantly elevated (OR = 3.2) especially in those with cardiovascular disease (OR = 7.3) compared with subjects who had never received a β-agonist, which can be partially attributed to the impact of β-adrenergic drugs on heart rate and the occurrence of arrhythmias [6].

The reports of increased risk of acute coronary syndromes in subjects inhaling β-adrenergic drugs [6–8] raise concerns about the safe use of 400-μg short-acting, β-adrenergic drugs in the bronchodilator test in elderly subjects. Until now, the risk of significant tachyarrhythmias that can lead to MI with the use of such a dosage of SABA in elderly subjects with concomitant heart diseases has not been established.

Aim

The primary goal of this study was to examine the relationship between inhaled β-agonist used in the bronchodilator test in older subjects and the risk of cardiovascular events including tachyarrhythmia.

Material and methods

Study population

For this study, we recruited 53 non-smoking subjects (45 women) aged 77; 68–82 who were admitted to the geriatric department of Wroclaw Medical University. The subjects were hospitalised during 2017–2019 for a comprehensive geriatric assessment. They were all in a stable clinical state. Subjects suffering from respiratory diseases and/or taking inhalation drugs were excluded from the study. Assessment of medical history, physical examinations, blood biochemistry, chest X-ray, 12-lead electrocardiogram, 24-hour Holter monitoring, bronchodilator test, and echocardiography were performed.

The detailed characteristics of the participants are presented in Table 1.

The research was approved by the Bioethical Committee at Wroclaw Medical University (reference number 417/2016). All subjects provided written informed consent.

Bronchodilator test

The bronchodilator test was conducted between 11 and 12 a.m. on the same day when Holter monitoring began. Before and during the test, the subjects did not perform any physical activities and did not smoke cigarettes.

Spirometry was performed before and 15 min after fenoterol inhalation using a Master Scope spirometer (Erlich Jaeger GmbH, Wurzburg, Germany) according to the recommendations of ATS/ERS [2]. Particular emphasis was placed on the test repeatability and acceptability criteria [2]. In the test, a dose of 400 μg of fenoterol (Bertec made by Boehringer Ingelheim) was administered (4 puffs of 100 μg) by an MDI inhaler under the supervision of the certified staff. The GLI2012 reference values were used to interpret the results. The bronchodilator test results were presented in percentages of the predicted and initial values.

24-hour Holter ECG monitoring

24-hour Holter ECG monitoring was performed using a 12-lead device produced by Lifecard CF (Reynolds Medical, Hertford UK). The obtained data were processed using specific software, and the reports were prepared by an experienced cardiologist. In this study, we compared the heart rate and the amount of ventricular and supraventricular extrasystoles (VE and SVE) an hour before and after the bronchodilator test.

Echocardiography examination

We used a two-dimensional, M-mode cardiovascular ultrasound system (Siemens Acuson X300). The examination was conducted in the left lateral decubitus position. All echocardiographic examinations were performed by an experienced cardiologist.

Statistical analysis

The data analysis was undertaken using Statistica 13 software (StatSoft). The Shapiro-Wilk test was performed to investigate the normal distribution of the sample. As the studied parameters were not normally distributed, non-parametric tests were used. The data were expressed as median (Me) and the interquartile
range 25–75%. The Kolmogorov-Smirnov or Friedman’s ANOVA test was performed to compare two independent samples. For dependent samples, the Wilcoxon or McNemar test was performed. The correlation between the variables was analysed by means of the Spearman test. A value of \( p < 0.05 \) was considered as statistically significant for all tests.

Results

A group of 53 subjects (45 women) aged 77.68–82 took part in the study. The subjects had not suffered from any respiratory tract diseases and had not used any inhalation medicines, including \( \beta \)-adrenergic drugs. The most common health problems in that population were hypertension (83% of the subjects) and coronary artery disease (CAD) (36%). In addition, 41% of the subjects were stroke survivors (Table 2). A total of 36% of the subjects used \( \beta \)-blockers and 13% used calcium channel blockers (Table 2).

Echocardiography

The echocardiography revealed a normal heart ejection fraction (EF) in all the study subjects (median 65; 60–65%). Diastolic dysfunction characteristics were found in 71% of the subjects. The majority of the subjects had confirmed heart valve dysfunctions. The most commonly occurring dysfunctions were mitral valve insufficiency (84%) and tricuspid valve insufficiency (81%). The other parameters are shown in Table 3.

Spirometry

The initial (before inhalation) spirometry showed a moderately severe obstruction in only one patient (FEV1 – 50% of predicted value). The other subjects did not have any pulmonary dysfunction. FEV1 median was 97% (68–106%) of the predicted value and FVC was 104% (68–149%) of the predicted value. After the drug inhalation, FEV1 improved by 5% (–17%; 22%), as compared to the initial value (Table 4).

24-hour Holter electrocardiographic monitoring

The Holter ECG monitoring readings taken an hour before and after the bronchodilator test were compared. In 6 (11%) subjects, atrial fibrillation was found, while the other subjects had the sinus rhythm. A slight but statistically significant increase in heart rate from 71/min to 79/min (median) was noted after the administration of fenoterol.

In 39% of the subjects, premature ventricular beats before drug administration were found. After fenoterol inhalation, such an abnormality occurred in 32% of the subjects (\( p < 0.001 \)). Premature supraventricular beats were found in 72% of the subjects before the bronchodilator reversibility test, and after drug inhalation (\( p = 0.01 \)) in 79%. However, when the number of ventricular and supraventricular beats during those periods was compared, no statistically significant differences were found (\( p = 0.42 \)) (Table 5).

| Parameter                  | Median | Interquartile range | N (%) |
|----------------------------|--------|---------------------|-------|
| EF                         | 65     | 64–65               | 25–75%|
| Mitral valve insufficiency | 45     | 42–48               | 84%   |
| Tricuspid valve insufficiency | 43   | 40–46               | 81%   |
| Atrium enlargement         | 23     | 21–26               | 43%   |
| Diastolic heart failure    | 38     | 36–40               | 71%   |
| Interventricular septal hypertrophy | 30   | 27–33               | 56%   |
| Aorta [mm]                 | 33     | 32–35               | 43%   |
| Left atrium [mm]           | 40     | 38–43               | 35%   |
| Left ventricular diameter diastole [mm] | 46   | 44–50               | 43%   |
| Left ventricular diameter systole [mm] | 28   | 25–32               | 50%   |
| Septum [mm]                | 12     | 10–13               | 13%   |
| Posterior wall [mm]        | 10     | 9–10                | 10%   |
| Right ventricle [mm]       | 26     | 25–28               | 28%   |

\( N \) – number of examined patients, \( \% \) – percent of examined patients.
Because 36% of the studied population was treated by β-blockers, which would influence the final results, we analysed them separately. Table 5 shows that the β-blocker group had a lower heart rate before (p < 0.001) and after fenoterol inhalation (p < 0.001) compared with the non-treated subjects. We found a significant increase in heart rate (p = 0.009) and the number of subjects with supraventricular beats in the β-blocker group (p = 0.02). No potentially dangerous arrhythmias or signs of CAD were found in the subjects.

In the non-treated group of subjects, we found a statistically significant increase in the number of subjects with supraventricular beats (p < 0.001) and a larger increase in heart rate after the inhalation of fenoterol (p = 0.04) than we observed in β-blocker-treated subjects (Figure 1).

No statistically significant impact of the SABA on the occurrence of tachycardia or other arrhythmias was found.

Discussion

The aim of our study was to investigate whether 400 µg of fenoterol, used in the bronchodilator test, would trigger an increase in heart rate and the development of tachyarrhythmias that could contribute to acute coronary syndrome in elderly subjects.

Until now, much attention has been focused on the effects of SABA on the heart conduction system and peripheral vascular system [4, 10–12]. Numerous studies have shown a noticeable chronotropic effect of inhaled and intravenous drugs in the healthy population [10, 12, 13], young people suffering from asthma [2, 14], and children [11, 15] treated for the exacerbation of asthma or COPD [16–19]. Lee et al. found an increased risk of tachyarrhythmias in subjects using long-acting β-adrenergic and parasympatholytic drugs [20]. Tachycardia was caused not only by the direct effect on β-adrenergic receptors of the heart but also by indirect activation of receptors causing vessels’ dilation and reaction of the vagus nerve [12, 21]. This effect is linked to a greater risk of an acute cardiovascular incident in the population

### Table 4. Spirometry test results before and after 400 µg fenoterol inhalation

| Parameter                  | Median | Interquartile range (25–75%) |
|---------------------------|--------|------------------------------|
| FEV₁ (before inhalation)  | 97     | 85–106                       |
| FVC (before inhalation)   | 104    | 89–117                       |
| FEV₁ (after inhalation)   | 103    | 89–121                       |
| FVC (after inhalation)    | 109    | 95–126                       |

FVC% pred – forced vital capacity % predicted, FEV₁% pred – forced expiratory volume in 1 s % predicted.

### Table 5. Frequency of occurrence of additional ventricular and supraventricular beats in patients (N = 53)

| Parameter                  | Before the test | After the test | P-value |
|---------------------------|-----------------|----------------|---------|
|                           | MED | Interquartile range | N (%) | MED | Interquartile range | N (%) |         |
| All studied patients:     |     |                        |       |     |                        |       |         |
| Heart rate [beats/min]    |  71 | 64–81                  |  75   | 69–83 | 0.020                  |
| VES per hour              |  0  | 0–2                    |  0    | 0–2   | 0.502                  |
| Occurrence of VES         |  3  | 0–34                   |  3    | 1–58  | 0.424                  |
| SVES per hour             | 38  | 72                     | 42    | 79    | 0.010                  |
| Occurrence of SVES        |     |                        |       |       |                       |
| Patients treated with β-blockers: |    |                        |       |       |                       |
| Heart rate [beats/min]    |  67 | 62–79                  |  71   | 69–81 | 0.009                  |
| VES per hour              |  0  | 0–1                    |  0    | 0–1   | 0.371                  |
| Occurrence of VES         |  6  | 31                     |  6    | 31    | 0.080                  |
| SVES per hour             |  4  | 1–30                   |  2    | 0–14  | 0.464                  |
| Occurrence of SVES        | 15  | 84                     | 14    | 74    | 0.024                  |
| Patients who were not treated with β-blockers: |    |                        |       |       |                       |
| Heart rate [beats/min]    |  73 | 65–82                  |  78   | 69–84 | 0.05                   |
| VES per hour              |  0  | 0–2                    |  0    | 0–3   | 0.484                  |
| Occurrence of VES         | 13  | 42                     |  11   | 35    | 0.12                   |
| SVES per hour             |  2  | 0–34                   |  2    | 1–58  | 0.799                  |
| Occurrence of SVES        | 13  | 42                     |  22   | 70    |                       |

VES – ventricular beats, SVES – supraventricular beats, N – number of examined patients, % – percent of examined patients.
Safety of bronchodilator reversibility test in elderly subjects: a prospective study

of patients treated with inhalation drugs, especially at the beginning of a therapy [6, 7, 9].

Because of these findings, a dosage of 400 µg of salbutamol or fenoterol used in the bronchodilator test in elderly subjects suffering from circulatory diseases and particularly CAD raises concerns. We conducted the β-adrenergic test in elderly subjects without respiratory tract diseases who had not used β-adrenergic drugs before. In this study, using 24-hour Holter ECG monitoring, we found that a slight post-inhalator increase in heart rate ($p = 0.006$) did not trigger the exacerbation of electrocardiographic signs of heart ischemia. Compared to baseline after the inhalation of fenoterol, no significant increase in the number of ventricular or supraventricular extrasystoles was observed in these subjects. However, after the drug inhalation, supraventricular extrasystoles occurred more often and ventricular premature beats less often in the studied population. No potentially dangerous arrhythmias were found among the examined subjects. However, we observed a significant increase in heart rate and the number of supraventricular beats in the non-β-blocker-treated group. Therefore, it can be concluded that using 400 µg of the short-acting β-adrenergic drug in elderly subjects is safe, but it should be performed with caution.

This study has some limitations. The group consisted of elderly subjects in a good general condition, and none of the subjects showed signs of heart failure, electrolyte imbalance, or respiratory impairments. The studies that have shown an increased risk of acute coronary syndrome [6, 7, 9] investigated populations with confirmed obstructive lung disease (asthma or COPD). This means that apart from the drug itself, other factors, such as exacerbation of the underlying disease, hypoxemia, electrolyte imbalance and other comorbidities, had an additional effect on the studied subjects. Future studies on the current topic are, therefore, recommended.

Conclusions

We observed only a slight but statistically significant increase in heart rate in subjects after the administration of 400 µg of inhaled fenoterol. However, there was a significant increase in the number of supraventricular beats in the subjects who had not taken β-blockers.

The study has shown that the older subjects did not experience potentially dangerous tachyarrhythmias after the administration of fenoterol. In subjects not treated by β-blockers or with concomitant serious heart disease, the bronchodilator test should be performed with caution.

Acknowledgments

The publication was prepared under a project financed from funds granted by the Ministry of Science and Higher Education in the “Regional Initiative of Excellence” programme for the years 2019-2022, project number 016/RID/2018/19, the amount of funding 11 998 121.30 PLN.

This work was supported by Wroclaw Medical University [grant number ST.310.16.089].

Conflict of interest

Anna Dor-Wojnarowska received financial support for attending the symposium EAACI 2018 from the company Chesi. Other authors declare no conflict of interest.

References

1. Global Initiative for asthma. Global Strategy for Asthma Management and Prevention 2018. https://ginasthma.org/gina-reports/.
2. Pellegrino R, Viegi G, Brusasco V, et al. Interpretative strategies for lung function tests. Eur Respir J 2005; 26: 948-68.
3. Insulander P, Juhlin-Dannfelt A, Freyschuss U, Vallin H. Electrophysiologic effects of salbutamol, a beta2-selective agonist. J Cardiovasc Electrophysiol 2004; 15: 316-22.
4. Cekici I, Valipour A, Kohansal R, Burghuber OC. Short-term effects of inhaled salbutamol on autonomic cardiovascular control in healthy subjects: a placebo-controlled study. Br J Clin Pharmacol 2009; 67: 394-402.
5. Burggraaf J, Westendorp RG, in’t Veen JC, et al. Cardiovascular side effects of inhaled salbutamol in hypoxic asthmatic patients. Thorax 2001; 56: 567-9.
6. Lee CH, Choi S, Jang EJ, et al. Inhaled bronchodilators and acute myocardial infarction: a nested case-control study. Sci Rep 2017; 7: 17915.
7. Neville E, Corris PA, Vivian J, et al. Nebulised salbutamol and angina. Br Med J 1982; 285: 796-7.
8. Au DH, Lemaître RN, Curtis JR, et al. The risk of myocardial infarction associated with inhaled beta-adrenoceptor agonists. Am J Respir Crit Care Med 2000; 161: 827-30.
9. Wang MT, Liou JT, Lin CW, et al. Association of cardiovascular risk with inhaled long-acting bronchodilators in patients with chronic obstructive pulmonary disease: a nested case-control study. JAMA Intern Med 2018; 178: 229-38.
10. Edgell H, Moore LE, Chung C, et al. Short-term cardiovascular and autonomic effects of inhaled salbutamol. Respir Physiol Neurobiol 2016; 231: 14-20.
11. Sarnaik SM, Saladino RA, Manole M, et al. Diastolic hypotension is an unrecognized risk factor for beta-agonist-associated myocardial injury in children with asthma. Pediatr Crit Care Med 2013; 14: e273-9.
12. Snyder EM, Wong EC, Foxx-Lupo WT, et al. Effects of an inhaled beta2-agonist on cardiovascular function and sympathetic activity in healthy subjects. Pharmacotherapy 2011; 31: 748-56.
13. Beloka SP, Janssen C, Woff E, et al. Effects of beta2-adrenergic stimulation on exercise capacity in normal subjects. Eur J Appl Physiol 2011; 111: 2239-47.
14. Eryonucu B, Uzun K, Güler N, Bilge M. Comparison of the acute effects of salbutamol and terbutaline on heart rate variability in adult asthmatic patients. Eur Respir J 2001; 17: 863-7.
15. Bio LL, Willey VL, Poon CY. Comparison of levalbuterol and racemic albuterol based on cardiac adverse effects in children. J Pediatr Pharmacol Ther 2011; 16: 191-8.
16. Virk MK, Hotz J, Khemani RG, et al. Change in oxygen consumption following inhalation of albuterol in comparison with levalbuterol in healthy adult volunteers. Lung 2017; 195: 233-9.
17. Brunetti L, Poiani G, Dhanaliwala F, et al. Clinical outcomes and treatment cost comparison of levalbuterol versus albuterol in hospitalized adults with chronic obstructive pulmonary disease or asthma. Am J Health Syst Pharm 2015; 72: 1026-35.
18. Zulkarneev R, Zagidullin N, Abdrahmanova G, et al. Ivabradine prevents heart rate acceleration in patients with chronic obstructive pulmonary disease and coronary heart disease after salbutamol inhalation. Pharmaceuticals 2012; 5: 398-404.
19. Lam S, Chen J. Changes in heart rate associated with nebulized racemic albuterol and levalbuterol in intensive care patients. Am J Health Syst Pharm 2003; 60: 1971-5.
20. Lee CH, Choi S, Jang EJ, et al. Inhaled bronchodilators and the risk of tachyarrhythmias. Int J Cardiol 2015; 190: 133-9.
21. Fowler SJ, Lipworth BJ. Pharmacokinetics and systemic beta2-adrenoceptor-mediated responses to inhaled salbutamol. Br J Clin Pharmacol 2001; 51: 359-62.